Browsing articles in "Dolor"
may
1
2013

¿Qué tratamientos son eficaces para el tratamiento del síndrome de dolor regional complejo en los adultos?

Síndrome de dolor regional complejoSe ha publicado una revisión de la Cochrane sobre la evidencia actual de distintas intervenciones terapéuticas en el Síndrome de dolor regional complejo.
Se basa en 6 revisiones Cochrane y 13 no Cochrane que incluyeron una amplia gama de tratamientos (fármacos, Rehabilitación, Cirugía, terapias alternativas…) en la mayoría de los casos, los artículos se basaban en estudios de baja calidad.
En forma de resumen:

  • El uso ketamina iv puede reducir eficazmente el dolor, aunque también se asocia con una aumento de efectos secundarios.
  • Bifosfonatos, la calcitonina y los programas imaginería motora graduada pueden ser eficaces en el SDRC (en general), y que la terapia del espejo puede ser eficaz en SDRC tras ictus. (baja calidad)
  • La fisioterapia y la terapia ocupacional no dieron lugar a beneficios clínicamente importantes en el seguimiento a un año. (baja calidad)
  • El bloqueo de los nervios simpáticos con anestesia local, no es eficaz. (baja calidad)
  • Hay pruebas de calidad moderada de que el bloqueo regional intravenoso con guanetidina no es eficaz y puede estar asociada con complicaciones.

Mostrar resumen »

Background:
There is currently no strong consensus regarding the optimal management of complex regional pain syndrome although a multitude of interventions have been described and are commonly used.

Objectives:
To summarise the evidence from Cochrane and non-Cochrane systematic reviews of the effectiveness of any therapeutic intervention used to reduce pain, disability or both in adults with complex regional pain syndrome (CRPS).

Main results:
We included six Cochrane reviews and 13 non-Cochrane systematic reviews. Cochrane reviews demonstrated better methodological quality than non-Cochrane reviews. Trials were typically small and the quality variable.

There is moderate quality evidence that intravenous regional blockade with guanethidine is not effective in CRPS and that the procedure appears to be associated with the risk of significant adverse events.

There is low quality evidence that bisphosphonates, calcitonin or a daily course of intravenous ketamine may be effective for pain when compared with placebo; graded motor imagery may be effective for pain and function when compared with usual care; and that mirror therapy may be effective for pain in post-stroke CRPS compared with a ‘covered mirror’ control. This evidence should be interpreted with caution. There is low quality evidence that local anaesthetic sympathetic blockade is not effective. Low quality evidence suggests that physiotherapy or occupational therapy are associated with small positive effects that are unlikely to be clinically important at one year follow up when compared with a social work passive attention control.

For a wide range of other interventions, there is either no evidence or very low quality evidence available from which no conclusions should be drawn.

Authors’ conclusions:
There is a critical lack of high quality evidence for the effectiveness of most therapies for CRPS. Until further larger trials are undertaken, formulating an evidence-based approach to managing CRPS will remain difficult.

This record should be cited as: O’Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD009416. DOI: 10.1002/14651858.CD009416.pub2
Assessed as up to date: March 1, 2013

abr
30
2013

Efectos de la imaginería motora graduada y sus componentes sobre el dolor crónico: una revisión sistemática y meta-análisis.

Terapia en espejoOs dejo una revisión sistemática y metaanálisis sobre el uso de imagineria motora graduada (GMI) y sus componentes en el dolor crónico (1).

Merece la pena una lectura detenida, como resumen podríamos destacar:

  • El número de ECA de buena calidad metodológica es aún pequeño.
  • La terapia en espejo es el componente más estudiado y con mejores fundamentos en el tratamiento del dolor, aunque el efecto de los resultados es muy variable.
  • La Imagineria motora parece menos efectiva que la terapia en espejo.
  • Los programas de GMI parecen ser más efectivos que la fisioterapia habitual (aunque se menciona un estudio prospectivo en el que se observa ausencia de resultados en el tratamiento del Síndrome de Dolor regional complejo)

1) Bowering KJ , O’Connell NE , Tabor A , Catley MJ , Leake HB , Moseley GL , Stanton TR .
Efectos de la imaginería motora graduada y sus componentes sobre el dolor crónico: una revisión sistemática y meta-análisis.
J Pain 2013 Jan; 14 (1) :3-13. doi: 10.1016/j.jpain.2012.09.007. Epub 2012 15 de noviembre

2)Johnson S, Hall J, Barnett S, Draper M, Derbyshire G,
Haynes L, Rooney C, Cameron H, Moseley GL, de C.
Williams AC, McCabe C, Goebel A: Using graded motor imagery for complex regional pain syndrome in clinical practice: Failure to improve pain. Eur J Pain 16:550-561, 2012

abr
22
2013

Ejercicio para mejorar los resultados tras fractura vertebral osteoporótica

EjercicioLos investigadores de la Cochrane realizaron una revisión de los efectos del ejercicio en personas con fracturas vertebrales osteoporóticas.
Siete estudios con un total de 488 personas cumplieron los criterios de inclusión.
Las conclusiones fueron:

  • No hay conclusiones definitivas se pueden hacer con respecto a los beneficios del ejercicio para las personas con fractura vertebral.
  • Aunque los ensayos individuales sí reportaron pequeños beneficios para el dolor, la función física y la calidad de vida, los resultados deben interpretarse con cautela debido a que fueron inconsistentes y la calidad de las pruebas fue muy baja.
  • El pequeño número de ensayos y la variabilidad entre los ensayos limita nuestra capacidad de dar conclusiones. La evidencia sobre los efectos del ejercicio después de una fractura vertebral, sobre todo para los hombres, es escasa.
  • Es necesario un ECA de alta calidad para informar sobre la prescripción de ejercicio para las personas con fracturas vertebrales.

En  los  Cochrane Summaries reflejaron lo siguiente (en términos sencillos):

  • En las personas con una fractura vertebral osteoporótica, no está claro si el ejercicio tiene un efecto sobre el dolor, la velocidad en la trasnferencia de sedestación a marcha, la velocidad de marcha o la calidad de vida.
  • No se encontraron estudios que analizasen si las personas tenían fracturas o caídas tras el inicio de un programa de ejercicios.
  • A menudo no se cuenta con información precisa acerca de los efectos secundarios y complicaciones. Sobre todo en  efectos secundarios poco frecuentes pero graves. No está claro si el ejercicio puede causar algún daño.

 

Mostrar Abstract »

Background:

Vertebral fractures are associated with increased morbidity (e.g., pain, reduced quality of life), and mortality. Therapeutic exercise is a non-pharmacologic conservative treatment that is often recommended for patients with vertebral fractures to reduce pain and restore functional movement.

Objectives:

Our objectives were to evaluate the benefits and harms of exercise interventions of four weeks or greater (alone or as part of a physical therapyintervention) versus non-exercise/non-active physicaltherapy intervention, no intervention or placeboon the incidence of future fractures and adverse events among adults with ahistory of osteoporotic vertebral fracture(s). We were also examined the effects of exercise on the following secondary outcomes: falls, pain, posture,physical function, balance,mobility, muscle function,quality of life and bone mineral densityof the lumbar spine or hip measured using dual-energy X-ray absorptiometry (DXA).We also reported exercise adherence.

Search strategy:

We searched the following databases: The Cochrane Library ( Issue 11 of 12, November 2011), MEDLINE (2005 to 2011), EMBASE(1988 to November 23, 2011), CINAHL (Cumulative Index to Nursing and Allied Health Literature, 1982 to November 23, 2011), AMED (1985 to November 2011), and PEDro (Physiotherapy Evidence Database, www.pedro.fhs.usyd.edu.au/index.html, 1929 to November 23, 2011. Ongoing and recently completed trials were identified by searching the World Health Organization International Clinical Trials Registry Platform (to December 2009). Conference proceedings were searched via ISI and SCOPUS, and targeted searches of proceedings of the American Congress of Rehabilitation Medicine and American Society for Bone and Mineral Research. Search terms or MeSH headings included terms such as vertebral fracture AND exercise OR physical therapy.

Selection criteria:

We considered all randomized controlled trials and quasi-randomized trials comparing exercise or active physical therapy interventions with placebo/non-exercise/non-active physical therapy interventions or no intervention implemented in individuals with a history of vertebral fracture and evaluating the outcomes of interest.

Data collection and analysis:

Two review authors independently selected trials and extracted data using a pre-tested data abstraction form. Disagreements were resolved by consensus, or third party adjudication. The Cochrane Collaboration’s tool for assessing risk of bias was used to evaluate each study. Studies were grouped according to duration of follow-up (i.e., a) four to 12 weeks; b) 16 to 24 weeks; and c) 52 weeks); a study could be represented in more than one group depending on the number of follow-up assessments. For continuous data, we report mean differences (MDs) of the change or percentage change from baseline. Data from two studies were pooled for oneoutcome using a fixed-effect model.

Main results:

Seven trials (488 participants, four male participants) were included. Substantial variability across the seven trials prevented any meaningful pooling of data for most outcomes. No trials assessed the effect of exercise on incident fractures, adverse events or incident falls. Individual trials reported that exercise could improve pain, performance on the Timed Up and Go test, walking speed, back extensor strength, trunk muscle endurance, and quality of life. However, the findings should be interpreted with caution given that there were also reports of no significant difference between exercise and control groups for pain, Timed Up and Go test performance, trunk extensor muscle strength and quality of life. Pooled analyses from two studies revealed a significant between-group difference in favour of exercise for Timed Up and Go performance (MD -1.13 seconds, 95% confidence interval (CI) -1.85 to -0.42, P = 0.002). Individual studies also reported no significant between-group differences for posture or bone mineral density. Adherence to exercise varied across studies. The risk of bias across all studies was variable; low risk across most domains in four studies, and unclear or high risk in most domains for three studies.

Authors’ conclusions:

No definitive conclusions can be made regarding the benefits of exercise for individuals with vertebral fracture. Although individual trials did report benefits for some pain, physical function and quality of life outcomes, the findings should be interpreted with caution given that findings were inconsistent and the quality of evidence was very low. The small number of trials and variability across trials limited our ability to pool outcomes or make conclusions. Evidence regarding the effects of exercise after vertebral fracture, particularly for men, is scarce. A high-quality randomized trial is needed to inform exercise prescription for individuals with vertebral fractures.

Giangregorio LM, MacIntyre NJ, Thabane L, Skidmore CJ, Papaioannou A.
Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD008618. DOI: 10.1002/14651858.CD008618.pub2
abr
19
2013

Inhibidores de la recaptación de serotonina y noradrenalina en Fibromialgia: Actualizacion Cochrane

Inhibidores recaptacion noradrenalina y serotoninaSe ha publicado una revisión Cochrane sobre el papel de los Inhibidores de la recaptación de serotonina y noradrenalina en la Fibromialgia.
Ya hemos hablado en otras ocasiones de distintos tratamientos farmacológicos en la Fibromialgia, con distintos resultados.
En ésta ocasión se observó una reducción del dolor con el tratamiento vs placebo, aunque no se observaron cambios substanciales en parámetros de fatiga, calidad de vida o en la calidad del sueño.
Podéis leer el resumen a continuación:

Mostrar resumen »

Abstract

Background

Fibromyalgia syndrome (FMS) is a clinically well-defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of life (QOL). Drug therapy focuses on reducing key symptoms and improving quality of life.

Objectives

To assess the benefits and harms of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo for treating FMS symptoms in adults.

Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library 2012, Issue 9), MEDLINE (1966 to September 2012), EMBASE (1980 to September 2012), www.clinicalstudyresults.org (U.S.-marketed pharmaceuticals) (to September 2012) and www.clinicaltrials.gov (to September 2012) for published and ongoing trials and examined the reference lists of reviewed articles.

Selection criteria

We selected randomized, controlled trials of any formulation of SNRIs against placebo for the treatment of FMS in adults.

Data collection and analysis

Two review authors independently extracted the data from the included studies, and assessed the risks of bias of the studies. Discrepancies were resolved by discussion.

Main results

Ten studies were included with a total of 6038 participants. Five studies investigated duloxetine against placebo, and five investigated milnacipran against placebo. A total of 3611 participants were included into duloxetine or milnacipran groups and 2427 participants into placebo groups. The studies had a low risk of bias in general. Duloxetine and milnacipran had a small incremental effect over placebo in reducing pain (standardized mean difference (SMD) -0.23; 95% confidence interval (CI) -0.29 to -0.18; 6.1% relative improvement). One-hundred and ninety-two participants per 1000 on placebo reported an at least 50% pain reduction compared to 280 per 1000 on SNRIs (Risk ratio (RR) 1.49, 95% CI 1.35 to 1.64; number needed to treat to benefit (NNTB) 11, 95% CI 9 to 15). Duloxetine and milnacipran did not reduce fatigue substantially (SMD -0.14; 95% CI -0.19 to -0.08; 2.5% relative improvement; NNTB 17, 95% CI 12 to 29), and did not improve QOL substantially (SMD -0.20; 95% CI -0.25 to -0.14; 4.6% relative improvement; NNTB 12, 95% CI 9 to 17) compared to placebo. There were no statistically significant differences between either duloxetine or milnacipran and placebo in reducing sleep problems (SMD -0.07; 95% CI -0.16 to 0.03; 2.5% relative improvement). One-hundred and seven participants per 1000 on placebo dropped out due to adverse events compared to 196 per 1000 on SNRIs. The dropout rate due to adverse events in the duloxetine and milnacipran groups was statistically significantly higher than in placebo groups (RR 1.83, 95% CI 1.53 to 2.18; number needed to treat to harm (NNTH) 11, 95% CI 9 to 13). There was no statistically significant difference in serious adverse events between either duloxetine or milnacipran and placebo (RR 0.78, 95% CI 0.55 to 1.12).

Authors’ conclusions

The SNRIs duloxetine and milnacipran provided a small incremental benefit over placebo in reducing pain. The superiority of duloxetine and milnacipran over placebo in reducing fatigue and limitations of QOL was not substantial. Duloxetine and milnacipran were not superior to placebo in reducing sleep problems. The dropout rates due to adverse events were higher for duloxetine and milnacipran than for placebo. The most frequently reported symptoms leading to stopping medication were nausea, dry mouth, constipation, headache, somnolence/dizziness and insomnia. Rare complications of both drugs may include suicidality, liver damage, abnormal bleeding, elevated blood pressure and urinary hesitation.

 

REFERENCIA:

Häuser W, Urrútia G, Tort S, Üçeyler N, Walitt B.

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.

Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD010292. DOI: 10.1002/14651858.CD010292.

Páginas:1234567891011»
UA-37655059-1